For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA).
Further details regarding the timings of this MTA will be available in due course.
| Status | Suspended |
| Decision | Selected |
| Process | TAG |
| ID number | 882 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 June 2016 | Suspended. For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA). Further details regarding the timings of this MTA will be available in due course. |
| 17 June 2016 | Draft scope documents |
For further information on our processes and methods, please see our CHTE processes and methods manual